Video

Educated Patient Lung Cancer Summit On-Demand: Dec. 12, 2020

Author(s):

CURE Media Group

View all three sessions of the CURE Educated Patient Lung Cancer Summit here!

View all three sessions of the CURE Educated Patient Lung Cancer Summit here!

Related Videos
Image of smiling doctor.
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
Image of woman with blonde hair.
Image of woman with blonde hair.
Image of woman with brown hair.
a man and a woman in front of a dark blue background for CURE Speaking Out
a man and a woman in front of a dark blue background for CURE Speaking Out
a man and a woman in front of a dark blue background for CURE Speaking Out
Related Content
Illustration of tumor.
March 28th 2025

Solnerstotug Demonstrates Early Efficacy in PD-L1 Resistant Tumors

Spencer Feldman
Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% disease control rate.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
CAN-2409 elicited responses among patients with pretreated stage 3/4 non–small cell lung cancer: © steph_photographis - stock.adobe.com
March 27th 2025

CAN-2409 Elicits Survival Responses In NSCLC

Alex Biese
Treatment with CAN-2409, an off-the-shelf immunotherapy, elicited responses among patients with pretreated stage 3/4 non–small cell lung cancer.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Image of cancer vaccine.
March 25th 2025

New Cancer Vaccine, EVM14, Cleared for Investigational Drug Application

Spencer Feldman
EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach this stage.
Image of lungs.
March 25th 2025

Olvi-Vec Shows Responses and Tolerable Safety in Small Cell Lung Cancer

Alex Biese
Positive preliminary data from the phase 1b/2 trial evaluating Olvi-Vec in small cell lung cancer have been announced.